Related Experiment Video

Updated: Jun 23, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML

Ing Soo Tiong1, David S Ritchie2, Piers Blombery3

  • 1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

The New England Journal of Medicine
|June 26, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Related Experiment Videos

Last Updated: Jun 23, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

Articles linked to this work by shared authors, journal, and citation graph.

Diagnosis and Management of Chronic Lymphocytic Leukemia with TP53 Loss of Function in the Novel Agent Era.

Blood·2026

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

British journal of haematology·2026

MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies.

Blood·2026

CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.

Blood·2026

A quantitative definition of the clinical manifestations of GATA2 deficiency in adults.

Blood·2026

Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment.

Blood neoplasia·2026

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

The New England journal of medicine·2026

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

The New England journal of medicine·2026

The Individual in Medicine: Why Anomalies Matter.

Journal of evaluation in clinical practice·2026

Reclassification of Noncanonical MET Splice-Site Variants Using RNA-Based Validation: A Practical Diagnostic Approach in Non-Small Cell Lung Cancer.

Turk patoloji dergisi·2026

Evolutionary and structural pathways of antibody maturation reveal principles for engineering potent SARS-CoV-2 neutralizers.

Journal of structural biology: X·2026

High-Throughput DNA Barcoding Identifies Lipid Nanoparticles for Lung Delivery of TRAIL-mRNA to Induce Tumor Cell Death in Experimental Metastasis Model.

International journal of nanomedicine·2026

Segmented poly(A) tails with microRNA target sites confer tissue-specific regulation for mRNA therapeutics.

Molecular therapy. Nucleic acids·2026

TGF-β-induced epithelial to mesenchymal transition drives proteoglycan binding specificity of HPV-based drug conjugates for cancer cells.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us